{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T21:00:39Z","timestamp":1763499639107},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Frequent supraventricular arrhythmia is associated with increased incidence of atrial fibrillation. However, it is unknown whether the prognostic significance of supraventricular arrhythmia is modified by plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) or troponin T (TnT). This study examined the interrelationships between NT-proBNP, TnT levels and frequent supraventricular arrhythmia, and whether these biomarkers and a measure of frequent supraventricular arrhythmia could improve risk assessment for incidence of AF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Supraventricular extrasystoles (SVEs) and supraventricular tachycardias were assessed from 24-h electrocardiograph recordings in 373 individuals initially without AF. Elevated NT-pro-BNP, TnT and SVEs was defined as a measurement in the top quartile of the study population distribution. Incident cases of AF were retrieved by linkage with the Swedish National Patient Register.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During a mean follow-up of 15.4\u00a0years, 88 subjects had a diagnosis of AF. After multivariable adjustment, individuals with both elevated NT-proBNP and frequent SVEs had a significantly increased incidence of AF, compared to subjects without elevated NT-proBNP or frequent SVEs (hazard ratio (HR) 4.61, 95% confidence interval (CI) 2.45\u20138.69), and compared to individuals with either elevated NT-proBNP or frequent SVEs (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). HRs for frequent SVEs alone or elevated NT-proBNP alone were 2.32 (95% CI 1.33\u20134.06) and 1.52 (95% CI 0.76\u20133.05), respectively. The addition of NT-pro-BNP and SVEs to a validated risk prediction score for AF, CHARGE-AF, resulted in improved prediction (Harrell\u2019s C 0.751 (95% CI 0.702\u20130.799) vs 0.720 (95% CI 0.669\u20130.771), <jats:italic>P<\/jats:italic>\u2009=\u20090.015).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Subjects with both elevated NT-proBNP and frequent SVEs have substantially increased risk of AF, and the use of these variables could improve long-term prediction of incident AF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-01942-6","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T09:06:09Z","timestamp":1615539969000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Jun","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders P.","family":"Persson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Engstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S. B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"1942_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949\u201353.","journal-title":"Eur Heart J"},{"key":"1942_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/archinte.158.3.229","volume":"158","author":"PA Wolf","year":"1998","unstructured":"Wolf PA, Mitchell JB, Baker CS, Kannel WB, D\u2019Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229\u201334.","journal-title":"Arch Intern Med"},{"key":"1942_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946\u201352.","journal-title":"Circulation"},{"key":"1942_CR4","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.jacc.2014.09.028","volume":"64","author":"RK Pathak","year":"2014","unstructured":"Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"1942_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/europace\/euy117","volume":"20","author":"ME Middeldorp","year":"2018","unstructured":"Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20:1929\u201335.","journal-title":"Europace"},{"key":"1942_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2007.09.026","volume":"51","author":"G Casaclang-Verzosa","year":"2008","unstructured":"Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol. 2008;51:1\u201311.","journal-title":"J Am Coll Cardiol"},{"key":"1942_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2014.02.555","volume":"63","author":"S Nattel","year":"2014","unstructured":"Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63:2335\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"1942_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/ehf2.12430","volume":"6","author":"JP Tsai","year":"2019","unstructured":"Tsai JP, Sung KT, Su CH, Lai YH, Kuo JY, Yun CH, et al. Diagnostic accuracy of left atrial remodelling and natriuretic peptide levels for preclinical heart failure. ESC Heart Fail. 2019;6:723\u201332.","journal-title":"ESC Heart Fail"},{"key":"1942_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.amjcard.2013.04.060","volume":"112","author":"T Kawasaki","year":"2013","unstructured":"Kawasaki T, Sakai C, Harimoto K, Yamano M, Miki S, Kamitani T. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112:867\u201372.","journal-title":"Am J Cardiol"},{"key":"1942_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijcard.2016.08.001","volume":"223","author":"E Svennberg","year":"2016","unstructured":"Svennberg E, Lindahl B, Berglund L, Eggers KM, Venge P, Zethelius B, et al. NT-proBNP is a powerful predictor for incident atrial fibrillation\u2014validation of a multimarker approach. Int J Cardiol. 2016;223:74\u201381.","journal-title":"Int J Cardiol"},{"issue":"31\u20138","key":"1942_CR11","first-page":"e3","volume":"169","author":"KB Filion","year":"2015","unstructured":"Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley RR, et al. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015;169(31\u20138):e3.","journal-title":"Am Heart J"},{"key":"1942_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCEP.107.754564","volume":"1","author":"S Nattel","year":"2008","unstructured":"Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62\u201373.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1942_CR13","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1161\/CIRCULATIONAHA.111.019893","volume":"124","author":"YK Iwasaki","year":"2011","unstructured":"Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124:2264\u201374.","journal-title":"Circulation"},{"key":"1942_CR14","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.109.874982","volume":"121","author":"Z Binici","year":"2010","unstructured":"Binici Z, Intzilakis T, Nielsen OW, K\u00f8ber L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation. 2010;121:1904\u201311.","journal-title":"Circulation"},{"key":"1942_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7326\/0003-4819-159-11-201312030-00004","volume":"159","author":"TA Dewland","year":"2013","unstructured":"Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, et al. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med. 2013;159:721\u20138.","journal-title":"Ann Intern Med"},{"key":"1942_CR16","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.hrthm.2015.04.042","volume":"12","author":"LS Johnson","year":"2015","unstructured":"Johnson LS, Juhlin T, Juul-M\u00f6ller S, Hedblad B, Nilsson PM, Engstr\u00f6m G. A prospective study of supraventricular activity and incidence of atrial fibrillation. Heart Rhythm. 2015;12:1898\u2013904.","journal-title":"Heart Rhythm"},{"key":"1942_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1253\/circj.CJ-16-0239","volume":"80","author":"A Alonso","year":"2016","unstructured":"Alonso A, Norby FL. Predicting atrial fibrillation and its complications. Circ J. 2016;80:1061\u20136.","journal-title":"Circ J"},{"key":"1942_CR18","doi-asserted-by":"publisher","first-page":"e000102","DOI":"10.1161\/JAHA.112.000102","volume":"2","author":"A Alonso","year":"2013","unstructured":"Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2:e000102.","journal-title":"J Am Heart Assoc"},{"key":"1942_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ahj.2016.05.004","volume":"178","author":"IE Christophersen","year":"2016","unstructured":"Christophersen IE, Yin X, Larson MG, Lubitz SA, Magnani JW, McManus DD, et al. A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am Heart J. 2016;178:45\u201354.","journal-title":"Am Heart J"},{"key":"1942_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2007.08.066","volume":"51","author":"AL Waldo","year":"2008","unstructured":"Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications. J Am Coll Cardiol. 2008;51:779\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"1942_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10654-009-9404-1","volume":"25","author":"JG Smith","year":"2010","unstructured":"Smith JG, Platonov PG, Hedblad B, Engstr\u00f6m G, Melander O. Atrial fibrillation in the Malm\u00f6 Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol. 2010;25:95\u2013102.","journal-title":"Eur J Epidemiol"},{"key":"1942_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.116.023163","volume":"136","author":"DH Lau","year":"2017","unstructured":"Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. Circulation. 2017;136:583\u201396.","journal-title":"Circulation"},{"key":"1942_CR23","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1093\/bioinformatics\/btr511","volume":"27","author":"MS Schr\u00f6der","year":"2011","unstructured":"Schr\u00f6der MS, Culhane AC, Quackenbush J, Haibe-Kains B. survcomp: an R\/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics. 2011;27:3206\u20138.","journal-title":"Bioinformatics"},{"key":"1942_CR24","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"1942_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/heartjnl-2017-311546","volume":"104","author":"G Boriani","year":"2018","unstructured":"Boriani G, Proietti M. Atrial fibrillation prevention: an appraisal of current evidence. Heart. 2018;104:882\u20137.","journal-title":"Heart"},{"key":"1942_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/europace\/eur389","volume":"14","author":"BH Chong","year":"2012","unstructured":"Chong BH, Pong V, Lam KF, Liu S, Zuo ML, Lau YF, et al. Frequent premature atrial complexes predict new occurrence of atrial fibrillation and adverse cardiovascular events. Europace. 2012;14:942\u20137.","journal-title":"Europace"},{"key":"1942_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1161\/CIRCULATIONAHA.115.016795","volume":"132","author":"JJ Goldberger","year":"2015","unstructured":"Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, et al. Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. Circulation. 2015;132:278\u201391.","journal-title":"Circulation"},{"key":"1942_CR28","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/eurheartj\/ehl109","volume":"27","author":"JP Goetze","year":"2006","unstructured":"Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006;27:1648\u201350.","journal-title":"Eur Heart J"},{"key":"1942_CR29","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.873265","volume":"120","author":"KK Patton","year":"2009","unstructured":"Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768\u201374.","journal-title":"Circulation"},{"key":"1942_CR30","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1136\/heartjnl-2013-304724","volume":"99","author":"KK Patton","year":"2013","unstructured":"Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, et al. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart. 2013;99:1832\u20136.","journal-title":"Heart"},{"key":"1942_CR31","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.jacc.2010.05.049","volume":"56","author":"JG Smith","year":"2010","unstructured":"Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56:1712\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1942_CR32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jacc.2007.09.064","volume":"51","author":"B Burstein","year":"2008","unstructured":"Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1942_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ahj.2013.07.004","volume":"166","author":"KM Eggers","year":"2013","unstructured":"Eggers KM, Al-Shakarchi J, Berglund L, Lindahl B, Siegbahn A, Wallentin L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J. 2013;166:541\u20138.","journal-title":"Am Heart J"},{"key":"1942_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijcard.2011.12.117","volume":"156","author":"T Anegawa","year":"2012","unstructured":"Anegawa T, Kai H, Adachi H, Hirai Y, Enomoto M, Fukami A, et al. High-sensitive troponin T is associated with atrial fibrillation in a general population. Int J Cardiol. 2012;156:98\u2013100.","journal-title":"Int J Cardiol"},{"key":"1942_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/joim.12114","volume":"274","author":"L Friberg","year":"2013","unstructured":"Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274:461\u20138.","journal-title":"J Intern Med"},{"key":"1942_CR36","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/europace\/euu165","volume":"16","author":"MA Baturova","year":"2014","unstructured":"Baturova MA, Lindgren A, Carlson J, Shubik YV, Bertil Olsson S, Platonov PG. Atrial fibrillation in patients with ischaemic stroke in the Swedish national patient registers: how much do we miss? Europace. 2014;16:1714\u20139.","journal-title":"Europace"},{"key":"1942_CR37","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","volume":"110","author":"DM Lloyd-Jones","year":"2004","unstructured":"Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042\u20136.","journal-title":"Circulation"},{"key":"1942_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1570161115666170201114835","volume":"15","author":"F Gragnano","year":"2017","unstructured":"Gragnano F, Golia E, Natale F, Bianchi R, Pariggiano I, Crisci M, et al. Von Willebrand factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target. Curr Vasc Pharmacol. 2017;15:404\u201315.","journal-title":"Curr Vasc Pharmacol"},{"key":"1942_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01942-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-021-01942-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01942-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T09:06:14Z","timestamp":1615539974000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-01942-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1942"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-01942-6","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided informed consent and the studies were approved by The Ethics Committee of Lund University. The study conforms to the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Those with both frequent supraventricular arrhythmia and elevated NT-proBNP have a high risk of future atrial fibrillation. This group could potentially benefit from primary prevention and efforts for early detection of AF.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical relevance and future perspective"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}